BAX

BCL2 associated X, apoptosis regulator

Explore in graph →CI-GENE-00021633HGNC:959 ENSG00000087088 NCBI 581 CIViC Approved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BAX mutation1
Venetoclax	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Resistance	2	submitted	EID12423 BAX mutation was found in AML samples that were refractory to venetoclax. In in vitro experiments, BH-3 mimetics enriches for BAX mutation. Deficiency of BAX impairs efficacy of BH-3 mimetics targetin… (full text at CIViC) PMID 36219880 · Moujalled et al., 2023 · Open in CIViC	civic
AXIN2 P455K + BAX L76R + BRAF V600E + CDKN2A Deletion + CDKN2B Deletion + TET2 E796KCDKN2B TET2 BAX AXIN2 BRAF CDKN2A1
Cobimetinib

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Glioblastoma (TCGA, Nature 2008) gbm_tcga_pub	Diffuse Glioma	Ssm	1	91	1.1%

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.